Manica Balasegaram

Executive Director of @gardp_amr and doctor dedicated to clinical and public health practice in infectious diseases, health policy & access to medicines.

[Manica Balasegaram @Manica_amr]

We need a new approach to antibiotics.

My latest piece on how more than 50 million deaths could be prevented by increasing access to antibiotics, published in @wef
https://t.co/g2ICbzBa4B

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

We’re thrilled to welcome Dr. José Gomes Temporão to GARDP’s Board!

As our first Board member from #LATAC, he brings invaluable expertise to the fight against #AMR.

📢 Learn more: https://t.co/lxiCXy8QI9

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

Infections are the 2nd leading cause of deaths for cancer patients. Without new #antibiotics, survival rates could start to decline

On this #WorldCancerDay, let’s commit to fighting #cancer & #AMR. Because survival should mean a second chance at life - not another battle for it

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

How more than 50 million deaths could be prevented by increasing access to antibiotics 💊

Read @Manica_amr piece in @wef

👇
https://t.co/HjZertwREy

[Drugs for Neglected Diseases initiative @DNDi]

📢 #WorldNTDDay is this Thursday 30 January!
This is a chance to raise awareness for the 1 billion+ people affected by neglected tropical diseases!

How you can help:
1️⃣ Download our messaging materials: https://t.co/OYz7bZeQNg
2️⃣ Share them on your channels this week.

#BeatNTDs

[Manica Balasegaram @Manica_amr]

As 2024 comes to a close, I’m proud of what we’ve achieved together. None of this would have been possible without the dedication, expertise, and passion of our team. Together, we’ll keep pushing forward to deliver life-saving treatments to those who need them most.

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

2024 was a pivotal year in the fight against #AMR💫

🔬 Zoliflodacin Phase 3 results
👶 Launch of NeoSep1 trial
🤝Cefiderocol tech transfer
🌍 New partnerships in India, Latin America & Korea
💡 EUR 60M in pledges

More in "2024: A Year in Review" 👇
https://t.co/RD8WZ0neq1

[Manica Balasegaram @Manica_amr]

Policy and regulatory interventions to address antibiotic shortages in low and middle-income countries

https://t.co/5k6o0ylagN

[Manica Balasegaram @Manica_amr]

@gardp_amr Balrogrrhoea

[Manica Balasegaram @Manica_amr]

Very honored to accept this award as a recognition of the work of GARDP and its key partners, especially our partnership with Innoviva Speciality Therapuetics, Inc. for the development of zoliflodacin.

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

Yesterday our Executive Director @Manica_amr was in #NYC for the #Fierce50 awards gala. ✨

The #Fierce50 is a groundbreaking project that highlights the people & companies driving meaningful change in #healthcare, pharma and #biotech.

Manica accepted the award for the Breakthroughs category on behalf of @gardp_amr.

[Manica Balasegaram @Manica_amr]

Fascinating article that deserves a more in-depth unpacking. It’s also relevant considering the evolved challenges in the antibiotic space today.

https://t.co/DAHNDydiaw

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

Yesterday our Executive Director @Manica_amr was in #NYC for the #Fierce50 awards gala. ✨

The #Fierce50 is a groundbreaking project that highlights the people & companies driving meaningful change in #healthcare, pharma and #biotech.

Manica accepted the award for the Breakthroughs category on behalf of @gardp_amr.

[Manica Balasegaram @Manica_amr]

India could be at the forefront of the solution.
With its scientific expertise, clinical resources and pharmaceutical sector, India has everything it needs to not only to tackle the AMR crisis within its borders but also to lead the way.

https://t.co/02vm3crYVm

[Manica Balasegaram @Manica_amr]

Excellent article on India’s locally developed new drugs and the game-changing solution they offer to preserve last-resort treatments.

We need more innovation and to learn from past mistakes.

https://t.co/A3GgThvdyT

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

We're looking forward to the #Fierce50 ceremony!

GARDP's Executive Director, @Manica_amr, has been lauded as a 2024 #Fierce50 honoree! 🎉 This recognition highlights his work in driving progress in the fight against #AMR.

[Manica Balasegaram @Manica_amr]

Conflicts often create conditions that are perfect for emergence and spread of drug resistance, a phenomenon first documented as early as the 1940s.

https://t.co/AYOp6ZDQLE

[Manica Balasegaram @Manica_amr]

Thanks @VikasReports for this great discussion about India's potential influence in tackling AMR.

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

Explore India’s potential influence in tackling #AMR in this episode of #ETMorningBriefPodcast by @EconomicTimes, with @Manica_amr

🎙️Tune in now https://t.co/uQN3VAqyMO @VikasReports

[CDC Director @CDCDirector]

It’s antibiotic awareness week! #AntimicrobialResistance (AR) kills an estimated 1 million people every year & is one of the greatest health threats we face today. To learn more about how to prevent AR, including through responsible antibiotic use, visit https://t.co/eIVzO8mvWd

[Shionogi Inc. (U.S.) @ShionogiUS]

Hear from Takuko Sawada, Director and Vice Chairperson of the Board, Shionogi & Co., Ltd. and Manica Balasegaram, Executive Director of @gardp_amr, about how we are working together to increase access to antibiotics, as part of addressing #AMR. #WAAW https://t.co/B24VI4gWLL

[Manica Balasegaram @Manica_amr]

The Superbug Fight Needs a Better Business Model
https://t.co/ERIRHtKdg7

[Manica Balasegaram @Manica_amr]

Public-health driven R&D and access is what we need, not just for antibiotics but for all conditions that affect children.

We are happy to be part of the GAP-f network to ensure that children, particularly in low- and middle-income countries, have equitable access to medicines.

[GAP-f @GAP_f_Network]

Advancing #paediatric formulations is crucial to ensure equitable, evidence-based care for #children with serious bacterial infections.

The report on #WHO's technical consultation which aims to facilitate regulatory pathways to accelerate access to effective treatments is available now! 🌍👶

📑👇https://t.co/1MQELSX7ZI

#AMR #WAAW #Bettermeds4kids

[ICANetwork @ICAfricaNetwork]

The Race Against Antimicrobial Resistance in Neonates:
Insights on Data, Infection Prevention, and Stewardship

Date: Tuesday, November 19, 2024
Africa Times: 11:30 p.m. GMT | 12:30 p.m. WAT | 1:30 p.m. CAT | 2:30 p.m. EAT

Register:
https://t.co/jjtvm7bjlq...